www.rsc.org/obc

Adenophostin A and analogues modified at the adenine moiety: synthesis, conformational analysis and biological activity

Charles N. Borissow,^a Steven J. Black,^a Michael Paul,^a Stephen C. Tovey,^b Skarlatos G. Dedos,^b Colin W. Taylor^b and Barry V. L. Potter^{*a}

^a Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, UK BA2 7AY. E-mail: b.v.l.potter@bath.ac.uk; Fax: +44 1225 386114; Tel: +44 1225 386639

^b Department of Pharmacology, Tennis Court Road, University of Cambridge, Cambridge, UK CB2 1PD

Received 1st October 2004, Accepted 3rd November 2004 First published as an Advance Article on the web 13th December 2004

The synthesis of adenophostin A (2) and two analogues [etheno adenophostin (4) and 8-bromo adenophostin (5)] modified at the adenine moiety, is reported. A combination of NMR analysis and molecular modelling was used to compare their structures in solution and determined that they all adopt very similar conformations. The analogues were tested for their ability to mobilise Ca^{2+} from DT40 cells expressing recombinant Type 1 rat $Ins(1,4,5)P_3R$ which reveals etheno adenophostin as a high affinity fluorescent probe of the $Ins(1,4,5)P_3R$. 8-Bromo adenophostin was only slightly less potent. The biological results support our current hypothesis regarding the binding mode of adenophostin A at the $Ins(1,4,5)P_3R$, *i. e.* that a cation- π interaction between the base moiety and Arg 504 of the receptor in combination with H-bonding may be responsible for the high potency of adenophostin A relative to $Ins(1,4,5)P_3$.

Introduction

D-myo-inositol 1,4,5-trisphosphate [Ins(1,4,5)P₃] (1) (Fig. 1) is a second messenger involved in the release of Ca^{2+} from intracellular stores upon interaction with its specific receptor [Ins(1,4,5)P₃R].¹



Fig. 1 Structures of D-*myo*-inositol 1,4,5-trisphosphate (1), adenophostin A (2) and adenophostin B (3).

Due to the biological importance of Ca^{2+} release² a number of analogues of $Ins(1,4,5)P_3$ have been synthesised and evaluated to determine the structural features required for interaction at its receptor.³ However, to date, none of these synthetic analogues has improved upon $Ins(1,4,5)P_3$ in terms of receptor binding affinity or Ca^{2+} release,³ with the exception of the dimeric species synthesised in our laboratories.⁴

Since their discovery⁵ and structural elucidation^{6,7} in 1993, adenophostin A 2 and B 3 have been the focus of much interest. Both molecules have been shown to exhibit a 10-fold greater affinity for the $Ins(1,4,5)P_3R^{8-13}$ than $Ins(1,4,5)P_3$ itself and are currently the most potent agonists of $Ins(1,4,5)P_3R$.⁷ These interesting properties have led to the widespread use of adenophostin A as a biological tool in Ca²⁺ signalling studies and prompted many groups, including our own, to develop synthetic routes to 2 and its analogues.^{9,10,14-32} None of these synthetic analogues has exceeded the potency of adenophostin A, but a great deal of information has been learned about adenophostin's structure–activity relationship at the $Ins(1,4,5)P_3R$ (see Fig. 2).

It has been demonstrated that the adenine base (or equivalent) of adenophostin A is an important structural feature necessary for high potency, although the exact reason for this has still to be determined.^{8,15,20,33,34} Our current explanation for this arose from modelling studies²⁰ based on the crystal structure of the binding domain of type 1 Ins(1,4,5)P₃R,³⁵ showing a possible cation– π interaction between the adenine ring and Arg504 when adenophostin A binds in the *anti*-conformation. This interaction may enhance binding affinity and improve the orientation of the 2'-phosphate resulting in an increase in potency. In an attempt to further elucidate these binding interactions, we report here the synthesis and conformational analysis of two analogues 4 and 5 (Fig. 3) modified at the adenine moiety.



Fig. 2 Summary of the structure–activity relationships of adenophostin A at the $Ins(1,4,5)P_3$ receptor.

This journal is © The Royal Society of Chemistry 2005

DOI: 10.1039/b415229



Fig. 3 Structures of etheno adenophostin (4) and 8-bromo adenophostin (5).

The etheno analogue 4 should provide an easily accessible fluorescent probe, which could be used for investigation of Ins(1,4,5)P₃Rs. A study by Rosenberg et al.²⁰ demonstrated that the $Ins(1,4,5)P_3R$ is tolerant to the introduction of large hydrophobic groups at N-6 of adenophostin. This, coupled with work by Leonard and co-workers^{36,37} showing that etheno derivatives bind like endogenous substrates to several proteins, indicated that 4 should be a good replacement for adenophostin A, hopefully retaining its high affinity binding to the $Ins(1,4,5)P_3R$. Earlier modelling studies by Hotoda et al.³³ suggest that adenophostin binds to the $Ins(1,4,5)P_3R$ in the syn-conformation as opposed to anti as devised from our docking experiments.²⁰ The 8-brominated analogue 5 is sterically constrained in the syn-conformation and might therefore exhibit a similar potency to adenophostin, or even higher, if the synconformation is maintained upon binding to the $Ins(1,4,5)P_3R$. The 8-bromo analogue also provides the versatility to produce potentially useful photoaffinity labels by either introducing an azido functionality directly at the 8-position or via an alkyl spacer. These compounds could be used for further investigation of Ins(1,4,5)P₃Rs.

Results and discussion

Synthesis

The synthesis of adenophostin A 2 and analogues 4 and 5 employs the 6-chloropurine building block 6 (Scheme 1), which we have previously shown to be a versatile intermediate. This



Scheme 1 Reagents and conditions: (a) EtOH, NH₃, 60 °C, 4 days; (b) i) (BnO)₂PNⁱPr₂, imidazolium triflate, DCM, RT, 1.5 h; ii) mCPBA, -78 °C, 10 min; (c) moist 20 % Pd(OH)₂/C, cyclohexene–MeOH–H₂O, 80 °C, 3 h.

has been reacted with a range of nucleophiles to produce a variety of N-6 base substituted adenophostin analogues²⁰ and is a convenient precursor for an improved route to adenophostin A. Treatment of **6** with ethanolic ammonia³⁸ gave the required 6-amino functionality with concomitant removal of the acetate protecting groups to afford **7** in 92% yield.

The introduction of the protected phosphates was achieved using freshly prepared imidazolium triflate and bis(benzyloxy) (diisopropylamino)phosphine.^{16,39} Oxidation of the trisphosphite with *m*CPBA furnished, after purification, the fully protected adenophostin intermediate **8** in 53% yield. Deprotection was achieved using catalytic transfer hydrogenation^{16,40} with the product being purified by ion exchange chromatography to give **2** in 75% yield. ¹H, ¹³C, ³¹P NMR and FAB mass spectral analysis were concurrent with those previously reported.^{16,32,41} Having synthesised adenophostin A, our attention now turned to its modification to both the etheno **4** and 8-bromo **5** analogues (Scheme 2).



Scheme 2 Reagents and conditions: (a) chloroacetaldehyde (50% aq.), NaOAc, 2 days; (b) 0.5 M NaOAc, Br₂, 60 h.

The synthesis of etheno nucleotides and nucleosides has been accomplished numerous times using slight modifications of a general procedure.^{36,37,42-45} Thus, adenophostin A was dissolved in a 50% aqueous solution of chloroacetaldehyde (pH 4.0–4.5) and was stirred for 48 h at room temperature. Purification using an MP1 AG ion exchange column gave the fluorescent etheno adenophostin analogue **4** showing characteristic doublets for H-10 and H-11 in the ¹H NMR spectrum at 8.22 and 8.87 ppm.

Like the etheno derivatives, a number of groups have previously synthesised 8-bromo analogues of nucleotides and nucleosides⁴⁶⁻⁵⁰ with the critical point being the need for a pH of between 4.0–4.5 for the reaction to proceed efficiently. This can be achieved using a sodium acetate buffer. In our case, an optimum concentration of 0.5 M sodium acetate was found to be sufficient, with the pH changing by only *ca*. 0.2 units over the course of the reaction. Adenophostin A was dissolved in 0.5 M sodium acetate buffer and a solution of bromine in buffer was slowly added. After stirring for 60 h, purification of the reaction mixture was achieved using an MP1 AG ion exchange column eluting with 150 mM TFA to give the desired 8-bromo analogue showing only one singlet in the ¹H NMR spectrum at 8.01 ppm representing H-2. The purity of analogues **4** and **5** was determined by HPLC showing >96% and >99% purity, respectively.

Conformational analysis in solution

Following the procedure of Hotoda *et al.*,³³ the ¹H and NOESY spectra of compounds **2**, **4** and **5** were recorded in 50 mM phosphate buffer (p^2 H 6.8) at 25 °C in an attempt to explore their conformation in solution. The results obtained for adenophostin



Fig. 4 NOESY spectra of (a) synthetic adenophostin A^a **2**; (b) etheno adenophostin 4^b ; (c) 8-bromo adenophostin 5^b . The structures of each compound are shown on the bottom right with the important NOE correlations highlighted. ^{*a*} Spectrum recorded in 50 mM phosphate buffer in D₂O (p²H 6.8) at 600 MHz with a mixing time of 800 ms at 298 K. ^{*b*} Spectra recorded in DMSO- d_6 at 400 MHz with a mixing time of 800 ms at 298 K.

Table 1 Selected coupling constants of adenophostin A 2, and analogues 4 and 5 and their calculated C-2' *endo* percentage^{α}.

	J _{1',2'} (Hz)	J _{3',4'} (Hz)	$[C-2' endo] \% J_{1',2'}/(J_{1',2'}+J_{3',4'})$	J _{1",2"} (Hz)	J _{2",3"} (Hz)	J _{3",4"} (Hz)	J _{4",5"} (Hz)
2	6.2	3.3	65%	3.7	9.5	9.5	9.5
4	5.7	3.5	62%	3.2	9.1	9.1	9.1
5	7.4	5.3	58%	3.8	9.4	9.4	9.4

 $^{\it a}$ All values were recorded in 50 mM phosphate buffer in D_2O (p^2H 6.8) at 400 MHz.

A (Table 1) paralleled those of Hotoda,³³ confirming: a chair conformation of the glucose ring with 2 equatorial phosphates; the close proximity of H-1" to H-3' as determined by NOE correlation; a preference for the C-2'-endo conformation of the ribose ring and a *syn*-orientation of the adenine moiety as determined from NOE correlations between H-8 and both H-1' and H-2' (Fig. 4a).

In order to model adenophostin A in solution, its structure (based on ¹H and NOESY NMR data) was surrounded by a "layer" of water molecules and energy minimisation calculations were performed to determine the lowest energy conformation. The model obtained (Fig. 5a) supports the data from the ¹H NMR experiments, showing a chair conformation of the glucose ring with 2 equatorial phosphates linked to a C-2' *endo* puckered ribose moiety. This is the major difference to the Hotoda *in* *vacuo* study which found the C-3' *endo* conformation in their lowest energy structure (although they state that the C-2' *endo* conformation is more likely). The NOESY experimental data is also supported, with the H-1" to H-3' distance being 2.37 Å, suitably close for a strong NOE correlation. The torsional angle about the N-glycosidic bond (χ^{\dagger}) is 6.4°, showing a *syn*conformation of the adenine moiety which is required for the NOE correlations between H-8 and H-1' and H-2'. Although there is a difference in χ between our model and Hotoda's (56°), both show the expected *syn*-conformation of the adenine moiety. This is observed because the energy barriers preventing rotation around the N-glycosidic bond are not high when compounds are in the C-2' *endo* conformation.⁵¹

Etheno adenophostin **4** gave markedly similar results to adenophostin A (Table 1), with the ribose moiety showing a preference for the C-2' *endo* conformer as determined by the Davies and Danyluk equation.⁵² The NOESY spectrum (see Fig. 4b) shows correlations between H-8 of the base with H-1' and H-2' of the ribose moiety suggesting a *syn* conformation in solution, similar to that of adenophostin A. Further NOE's show the expected interactions of H-10 with both H-11 and H-2

[†] The torsional angle about the N-glycosidic bond (Cl'–N) is the angle between the Cl'–O bond and the N9–C4 bond. Therefore, when $\chi = 0^{\circ}$ the O–Cl' bond is eclipsed by the N9–C4 bond. When $\chi = 0 \pm 90^{\circ}$ the base is said to be in the *syn* conformation with the *anti* conformation being $\chi = 180 \pm 90^{\circ}$.



Fig. 5 Minimum energy solution phase conformations of (a) adenophostin A 2; (b) etheno adenophostin 4; (c) 8-bromo adenophostin 5. For ease of viewing the water molecules have been removed.

and also the correlation between H-3' and H-1". The proton– proton coupling constants of the glucose ring confirm the presence of a chair conformation with two equatorial phosphate groups. Modelling studies were performed in the same manner as described previously for adenophostin A, resulting in the low energy structure seen in Fig. 5b. The carbohydrate backbone of the molecule remains essentially unchanged; however, there is a substantial change in χ from 6.4 to -76.0° probably resulting from the increase in electron density of the aromatic system being repelled by the C-2' phosphate. Despite this large change, the adenine moiety remains in the *syn*-conformation which would allow the observed NOE correlations of H-8 with H-1' and H-2'.

8-Bromo adenophostin (5), not unexpectedly, follows the same pattern as adenophostin A (2) and etheno adenophostin (4) (Table 1), assuming the same conformation in terms of glucose and ribose moieties. The NOESY spectrum (Fig. 4c) shows no visible correlations between H-2 and any other protons suggesting the same *syn*-conformation of the base moiety. Modelling of the 8-bromo analogue (Fig. 5c) confirms the retention of conformation within the glucose and ribose moieties, as expected from NMR data, but again a change in χ is observed from 6.4° in 2 to 63.2° in 5. This rotation about the N-glycosidic linkage is caused by steric clashes between the bulky bromine atom and the ribose moiety making the *syn*-conformation more energetically favourable. Similar observations were made in the crystal structure of 8-bromo adenosine.⁵³

Biological evaluation

Compounds 4 and 5 were evaluated in DT40 cells, expressing recombinant Type 1 rat $Ins(1,4,5)P_3R$, for their ability to release Ca^{2+} from intracellular stores (Table 2). The results for $Ins(1,4,5)P_3$ (1) and adenophostin A (2), synthesised by this present route, are also shown and all values are shown relative to adenophostin A measured in parallel experiments for a more accurate comparison.

The EC₅₀ value of adenophostin A was *ca.* 10 times lower than that of Ins(1,4,5)P₃ (EC₅₀ 24.8 and 2.1 nM, respectively), consistent with previous results and confirming its higher potency. The drop in potency of the etheno analogue **4** was modest, its EC₅₀ being 65% that of adenophostin A. Interestingly, the 8-bromo compound **5** was still half as potent as adenophostin A (**2**), with a 4 fold increase in potency over Ins(1,4,5)P₃ (**1**).

Table 2 ⁴⁵Ca²⁺ Release data for 1, 2 4 and 5 from DT40 cells^a

Despite the *syn*-conformation of adenophostin A in solution, our proposed model for its binding to the $Ins(1,4,5)P_3R^{20}$ places the adenine moiety of adenophostin in the *anti*-conformation allowing the possibility of a cation- π interaction between the base and the guanidinium sidechain of Arg 504 (Fig. 6a).

Cation– π interactions have been observed numerous times,^{54–56} with calculations predicting that the interaction may



Fig. 6 Predicted binding modes of (a) adenophostin A and (b) etheno adenophostin with the $Ins(1,4,5)P_3R^{20}$. The adenine moiety (or equivalent) is in the *anti*-conformation showing a possible cation $-\pi$ interaction with Arg 504. Adapted from ref. 20

	EC ₅₀ /nM	max. Response/%	h	EC_{50} with respect to 2^{b}	п	
1 2 4 5	$24.8 \pm 2.1 \\ 2.1 \pm 0.6 \\ 4.0 \pm 0.6 \\ 5.4 \pm 0.6$	78 ± 2 76 ± 1 80 ± 1 79 ± 3	$\begin{array}{c} 1.21 \pm 0.06 \\ 1.54 \pm 0.13 \\ 1.69 \pm 0.16 \\ 1.93 \pm 0.11 \end{array}$	$\begin{array}{c} 0.09 \pm 0.01 \\ 1.0 \\ 0.65 \pm 0.05 \\ 0.49 \pm 0.05 \end{array}$	11 12 3 4	

^{*a*} Results (means \pm SEM of *n* independent experiments) show the concentration of each compound causing half the maximal response (EC₅₀), the Hill coefficient (*h*) and the maximal response (% of intracellular Ca²⁺ stores released) for each of the four compounds. ^{*b*} Results are expressed relative to the effect of **2** in parallel, with values lower than 1 denoting compounds of lower potency than **2**.

be stronger than a typical salt bridge in an exposed aqueous environment⁵⁷ such as we see in the Ins(1,4,5)P₃R. The crystal structures of the NADP⁺-dependent aldehyde dehydrogenase,58 tropinone reductase I⁵⁹ and 6-phosphogluconate dehydrogenase60 are of particular interest due to the structural similarities of parts of the cofactor for these enzymes and adenophostin A. All three examples show interactions of an arginine residue with both the adenine moiety (cation $-\pi$) and the 2'-phosphate group (from NADP+ for the first two and 2'-AMP for the last), corresponding well with our current model. Earlier work on ribophostin,⁶¹ an adenophostin analogue without the base, had shown that the adenine moiety (or equivalent) is essential for high potency with the ribophostin EC_{50} for Ca^{2+} release increasing compared to that of $Ins(1,4,5)P_3$. This suggests that a synergistic effect of the 2'-phosphate group and the adenine moiety interacting with Arg 504, combined with H-bonding at N-3 from Arg 269, may be the reason for the 10-fold increase in potency of adenophostin over $Ins(1,4,5)P_3$. The energy gain from these strong interactions should be more than sufficient to overcome the weak energy barriers imposed upon interconversion from a syn- to anti-conformation.51

The slight decrease in potency of etheno adenophostin 4 relative to 2 may be caused by the increase in electron density of the base repelling the C-2' phosphate therefore disrupting its optimal orientation in the receptor. A more likely explanation is that the additional ring of the etheno analogue disrupts the electrostatic potential of the base moiety which, in turn, lowers the energy of the cation- π interaction. Studies concerning these interactions have shown that aromatics with areas of high electrostatic potential at their centre form the strongest cation- π interactions and that electron rich heterocycles are quite poor cation– π binders.^{62,63} However, docking experiments have shown a virtually identical orientation of the etheno analogue (Fig. 6b) when compared to adenophostin A which would allow cation- π interactions with Arg 504. Fig. 6b illustrates the space available around the proposed adenine binding pocket for occupation by modified bases, such as etheno adenine.

The lower activity of 8-bromo adenophostin 5 relative to 2 was not expected based on Hotoda's study33 but corresponds well with our model. However, an EC_{50} value higher than $Ins(1,4,5)P_3$ (1) was surprising due to the requirement of an anti-conformation for high affinity binding and the steric restraints imposed to prevent this. This suggests that the ligand-receptor complex could be of sufficiently low energy to overcome the steric repulsion in the transition between the syn- and anti-conformations. The energy required to overcome this transitional barrier leads to a loss in potency, with 5 being approximately half as active as adenophostin A. Similar findings have been observed for ligand-receptor complexes of 8-BrADP^{64,65} and 8-BrNAD⁺,⁶⁵ both ligands binding as the anti-conformer despite being in the syn-conformation when unbound. Interestingly, protein bound adenosine derivatives binding in the synconformation have been found, however, there are only a few reported cases.66-68

Fluorescence properties

The fluorescence emission of etheno adenophostin in 0.1M HEPES buffer at varing pH is shown in Fig. 7. The fluorescence emission is greatest at pH 7.0, forming a single unresolved band with a maximum at 412 nm, indicating that etheno adenophostin could be a valuable tool for the investigation of $Ins(1,4,5)P_3Rs$ at physiological pH.

Conclusions

We have synthesised two adenophostin analogues 4 and 5, modified at the adenine moiety. Etheno adenophostin 4 is a high affinity fluorescent probe which could be used at physiological pH for the investigation of $Ins(1,4,5)P_3Rs$. 8-Bromo adenophostin 5 has



Fig. 7 Variation in fluorescence emission intensity of etheno adenophostin **4** with pH in 0.1 M Hepes buffer. Excitation at 296 nm.

further applications in the synthesis of potential photoaffinity analogues and other 8-modified adenophostin analogues. We propose that two conformations of adenophostin A exist dependent on whether in solution or bound to the $Ins(1,4,5)P_3R$ with NMR and modelling data supporting this. We suspect that the proposed cation– π interaction between the base moiety of adenophostin and its analogues with Arg 504 is at least partly responsible for their increased potency relative to $Ins(1,4,5)P_3$ and this model warrants further investigation.

Experimental

General

Chemicals were purchased from Acros, Aldrich, Sigma and Fluka. All anhydrous solvents were purchased from either Aldrich or Fluka. RPMI 1640 medium, L-glutamine, 2mercaptoethanol and G-418 were from Invitrogen, sera were from Sigma and Mag-fluo-4AM was from Molecular Probes. TLC was performed on precoated plates (Merck aluminum sheets silica 60 F₂₅₄, Art. No. 5554). Products were visualised under UV light and by dipping into phosphomolybdic acid in MeOH followed by heating or by dipping into anisaldehyde in EtOH followed by heating. Radial-band chromatography (RBC) was performed using a Chromatotron (7924T, TC Research, UK) with Adsorbosil Plus-P (6-15 µm) (Alltech) as the adsorbent. Ion exchange chromatography was performed on an LKB-Pharmacia medium pressure ion-exchange chromatograph using MP1 AG ion-exchange resin and a gradient of 0-100% 150 mM TFA as eluent. ¹H NMR, NOESY and ¹³C spectra were recorded on JEOL JMN GX-270, EX-400 or Varian Inova-600 NMR spectrometers. ³¹P NMR spectra were recorded on JEOL JMN GX-270 or EX-400 NMR spectrometers and chemical shifts were measured in ppm and denoted positive downfield from external 85% H₃PO₄. All coupling constants are quoted in Hz. Melting points were determined using a Reichert-Jung Therm Galen Kofler block and are uncorrected. Low resolution mass spectra were recorded at the University of Bath Mass Spectrometry Service using +ve and -ve fast atom bombardment (FAB) with *m*-nitrobenzyl alcohol as the matrix. High resolution accurate mass spectra were recorded at the University of Bath Mass Spectrometry Service. Optical rotations were measured at ambient temperature using an Optical Activity Ltd AA-10 polarimeter in a cell volume of 1 cm³ or 5 cm³ and specific rotation are given in 10⁻¹ deg cm³ g⁻¹. Fluorescence measurements were made on a Perkin Elmer LS 50B fluorimeter. UV spectra were recorded using a Perkin Elmer Lambda EZ201 spectrometer. HPLC analysis was carried out on a Hewlett-Packard series chromatograph with a strong anion-exchange resin (MP1 AG, column size 3×150 mm). A linear gradient of 0-50% 150 mM TFA was used as eluent at 1 cm³ min⁻¹

over 60 min, with the UV detector set at 254 nm. Synthetic phosphates were assayed using an adaptation of the Briggs phosphate test.⁶⁹

Molecular modelling experiments

Initially, force field modelling and stochastic conformational searching with MOE (2003.2) did not find global minimum structures that could easily be reconciled with the NOE and ¹H NMR data. *Ab initio* modelling with Gaussian 98-RevA.6, running on a SGI Octane2, IRIX 6.54 was attempted with HF/3–21G*, B3LYP/3–21G* and CPCM/B3LYP/6–31+G(d) but failed to find satisfactory minima structures with proton steric clashes in accordance with the NOE data. Modelling the phosphate anion moieties with SCRF continuum models may result in an energetic conflict between electrostatic repulsions between phosphate anion and the tendency of SCRF envelopes to minimise the volume of solvent cavities.

Favourable results were obtained when explicit water molecules were included. Using MOE, Linux RedHat10, the structures were drawn and dihedral angles adjusted to reflect the NOE and ¹H NMR data. A 6 Å spherical water envelope was then placed around the solutes with the water soak facility in MOE. The solutes were fixed and the water molecules minimised with MMFF94 with non bonding cut-off adjusted to 12 Å. Once complete, the structures were minimised using Mopac2002, implemented in Cache-Pro6.11 running windows98rev2, on a Desktop (Dell) PC without constraints. The semi-empirical method PM5 was used as implemented in Mopac2002. Extra keywords were used in Mopac2002 to enable reasonable convergence, PRECISE, LET DDMIN = 0.00 GEO-OK, GRAD, GNORM = 0.1. Cosmo solvation was not used and the clusters were simply treated as gas phase entities. Minimised solute structures are shown with explicit solvent molecules hidden.

Stable transfection of DT40 cells with rat Ins(1,4,5)P₃R1

The open reading frame of rat $Ins(1,4,5)P_3R1$ was amplified by PCR from the expression vector pCMVI-9-Ins(1,4,5)P₃R1⁷⁰ using the following primers: 5'-AGGAATTCG-CCACCATG-TCTGACAAAATG-3' and 5'-CCGGTACCG-AATTCTTA-GGCTGGCTGCTGT-3' and cloned as an EcoRI fragment into pcDNA3 (Invitrogen). The chicken β -actin hybrid promoter⁷¹ was excised from the vector pAneo⁷² and cloned in place of the CMV promoter upstream of the Ins(1,4,5)P₃R1 open reading frame to create the construct pcDNA3-Ins(1,4,5)P₃R1. DT40 cells in which the genes for all three endogenous $Ins(1,4,5)P_3R$ subtypes have been deleted (DT40/InsP₃R-KO)⁷³ were stably transfected by electroporation with linearized pcDNA3-Ins(1,4,5)P₃R1 using a Gene Pulser apparatus (Bio-Rad Laboratories) at 330 V, 500 μ F with 5 μ g DNA/10⁶ cells. Clonal isolation was carried out in the presence of 2 mg ml⁻¹ G-418 and positive clones were amplified and screened for the presence of rat $Ins(1,4,5)P_3R1$ by western blotting using an anti-peptide antiserum⁷⁴ corresponding to the C-terminal 15-residues of rat Ins(1,4,5)P₃R1.

Cell culture

DT40/Ins(1,4,5)P₃R–KO cells stably expressing recombinant rat InsP₃R1 (DT40/Ins(1,4,5)P₃R1 cells) were cultured in suspension in RPMI 1640 medium supplemented with foetal bovine serum (10%), L-glutamine (2 mM), 2-mercaptoethanol (50 μ M) and heat-inactivated chicken serum (1%). Cells were incubated in a humidified atmosphere (95% O₂; 5% CO₂ at 37 °C) and passaged every 2–3 days when they had reached a density of *ca*. 2×10^6 cells ml⁻¹.

Measurement of Ca²⁺ release from permeabilized cells

The effects of $Ins(1,4,5)P_3$ on intracellular Ca^{2+} stores were measured using a low-affinity Ca^{2+} -indicator trapped within the

intracellular stores of permeabilized cells. DT40/Ins(1,4,5)P₃R1 cells were harvested by centrifugation (650 \times g; 2 min) and resuspended $(2-3 \times 10^7 \text{ cells ml}^{-1})$ in Hepes-buffered saline (HBS: 135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl₂, 1.5 mM CaCl₂, 11.6 mM Hepes, 11.5 mM D-glucose, pH 7.3) supplemented with Mag-fluo-4AM (20 µM), Pluronic F-127 (0.05%) and bovine serum albumin (1 mg ml⁻¹). After 1 h at 20 °C in the dark, the Mag-fluo-4-loaded cells were harvested (650 \times g; 2 min) and re-suspended (ca. 2×10^6 cells ml⁻¹) in Ca²⁺-free cytosolic-like medium (CLM: 140 mM KCl, 20 mM NaCl, 2 mM MgCl₂, 1 mM EGTA, 20 mM Pipes, pH 7.0). The cells were permeabilized by incubation with saponin (10 µg ml⁻¹, 4 min at 37 °C), harvested $(650 \times g; 2 \text{ min})$ and resuspended in Mg²⁺-free CLM (140 mM KCl, 20 mM NaCl, 1 mM EGTA, 375 µM CaCl₂ (ca. 200 nM free [Ca²⁺]), 20 mM Pipes, pH 7.0). The permeabilized cells (with Mag-fluo-4 trapped within the lumen of the ER) were then attached to 96-well plates (ca. 8×10^5 cells per well) coated with poly-L-lysine (0.01%) and centrifuged onto the plate (300 \times g; 2 min). Immediately before an experiment, the cells were washed twice in Mg²⁺-free CLM to remove cytosolic Mag-fluo-4 and the plates were then mounted in a Flexstation fluorescence plate reader (Molecular Devices, Sunnyvale, CA), which allows automated additions to the sample wells while recording fluorescence. Mag-fluo-4 fluorescence was monitored by excitation at 485 nm with emission detected at 520 nm. Active Ca²⁺ uptake into the ER was initiated by addition of Mg²⁺-ATP (1.5 mM) and after 150 s, when the stores had loaded to a steady-state Ca2+ content, Ins(1,4,5)P3 was added. The amount of Ca2+ released by Ins(1,4,5)P3 was expressed as a fraction of the total Ca²⁺ content of the ER as assessed by addition of $1 \,\mu M$ ionomycin. Data are presented as means \pm s.e. means from n independent experiments, each performed in triplicate.

Concentration–effect relationships were fitted to fourparameter logistic equations using non-linear curve-fitting procedures (GraphPad Prism, San Diego, CA).

2",5',6"-Tri-O-benzyl-3'-O-a-D-glucopyranosyl adenosine (7). A mixture of 2',3",4"-tri-O-acetyl-2",5',6"-tri-O-benzyl-3'-O-a-Dglucopyranosyl-6-chloro-9-β-D-ribofuranosidopurine 6 (44 mg, 52.1 µmol) in ethanolic ammonia (3 cm³) was heated at 60 °C in a pressure tube for 72 h. The mixture was concentrated under reduced pressure and was purified by radial band chromatography (RBC) (ethyl acetate \rightarrow ethyl acetate-methanol 14 : 1) to give the title compound 7 (33 mg, 92%). mp 93–97 °C (from ethanol) (lit.¹⁶ mp 95–115 °C); $[a]_{D}^{22}$ 5.7 (c = 1.06, CHCl₃) (lit.¹⁶ $[a]_{D}^{25}$ –2.3 $(c 2.6, CHCl_3)$; $\delta_{\rm H}(270 \text{ MHz}; CDCl_3; Me_4Si) 3.43 (1 \text{ H}, dd, J_{1'',2''})$ 3.5, J_{2",3"} 9.9, H-2"), 3.52–3.78 (5 H, m, H-5'_A, H-5'_B, H-4", H- $6''_{\text{A}}$, H- $6''_{\text{B}}$), 3.86–3.96 (1 H, m, H-5''), 4.09 (1 H, t, $J_{2'',3''} = J_{3'',4''}$ 9.9, H-3"), 4.24-4.30 (1 H, m, H-3'), 4.35-4.40 (1 H, m, H-4'), 4.45-4.56 (4 H, m, 2 × OCH₂Ar), 4.59-4.83 (3 H, m, OCH₂Ar, H-2'), 4.90 (1H, d, *J*_{1",2"} 3.5, H-1"), 6.10 (1 H, d, *J*_{1',2'} 6.7, H-1'), 6.34 (2 H, s, NH₂), 7.21-7.39 (15 H, m, ArH), 8.05, 8.26 (2 H, 2 s, H-2, H-8); δ_c(100.5 MHz; CDCl₃; Me₄Si) 69.85 (C-6"), 70.19 (C-5' and C-4"), 72.58 (C-5"), 72.98 (C-3"), 73.90, 73.93, 74.30 $(3 \times OCH_2Ar)$, 75.93 (C-2'), 79.64 (C-2"), 80.28 (C-3'), 83.21 (C-4'), 87.97 (C-1'), 99.77 (C-1"), 119.47 (C-5), 127.84, 127.97, 128.17, 128.54, 128.61, 128.78, 128.83, 128.96 (ArCH), 137.04. 137.65, 138.17 (3 × ipso-C of Bn ring), 139.04 (C-8), 149.62 (C-4), 152.90 (C-2), 155.68 (C-6); m/z (FAB) 700.1 [(M + H)⁺, 70%]; (mass calcd for $C_{37}H_{42}N_5O_9$ (M + H)⁺, 700.29826; found 700.29749.

2",5',6"-Tri-O-benzyl-2',3",4"-tris(dibenzyloxyphosphoryl)-3'-O-a-D-glucopyranosyl adenosine (8). A mixture of the triol 7 (382 mg, 0.55 mmol), bis(benzyloxy) (diisopropylamino)phosphine (631 mg, 1.83 mmol) and imidazolium triflate³⁹ (393 mg, 1.82 mmol) in anhydrous DCM (4 cm³) was stirred at room temperature under N₂ for 90 min. TLC (ethyl acetate-hexane, 7 : 3) indicated the complete conversion to the trisphosphite so water (2 drops) was added and the reaction was cooled to -78 °C. mCPBA (331 mg, 1.93 mmol) was added, followed after 10 min by 10% aq. Na₂SO₃ (10 cm³) and ethyl acetate (20 cm³). The reaction was allowed to attain room temperature with the organic phase being washed consecutively with sat. NaHCO₃ (20 cm³) and brine (20 cm³), dried (MgSO₄) and concentrated under reduced pressure. Purification by RBC (CHCl₃-acetone 4 : 1 \rightarrow 6:4) furnished the fully protected trisphosphate 8 (431 mg, 53%). $\delta_{\rm H}$ (270 MHz; CDCl₃; Me₄Si) 3.50–3.70 (5 H, m, H-5'_A, H-5'_B, H-2", H-6"_A, H-6"_B), 3.79–3.88 (1 H, m, H-5"), 4.12 (1 H, AB, J_{AB} 7.3, 0.5 × OCH₂Ar) $4.26-4.86 (14 \text{ H}, \text{m}, 5.5 \times \text{OC}H_2\text{Ar}, \text{H-3'}, \text{H-4'}, \text{H-4''}), 4.87-5.06$ (8 H, m, 3.5 ×; OCH₂Ar, H-3"), 5.32 (1H, d, $J_{1",2"}$ 3.7, H-1"), 5.56–5.66 (1 H, m, H-2'), 5.70 (2 H, br s, NH₂), 6.34 (1 H, d, J_{1',2'} 6.6, H-1'), 6.94-7.41 (45 H, m, ArH), 7.90, 8.25 (2 H, 2 s, H-8, H-2); δ_c(100.5 MHz; CDCl₃; Me₄Si) 68.64 (C-6"), 69.44–70.41 $(C-5', 6 \times POCH_2Ar \text{ with } C-P \text{ coupling}), 70.16 (C-5''), 71.91,$ 73.66, 73.90 (3 × OCH₂Ar), 74.10 (C-4"), 74.68 (C-3'), 77.04 (C-2"), 77.55 (C-2' with C-P coupling), 78.39 (C-3" with C-P coupling), 82.72 (C-4'), 85.89 (C-1'), 95.67 (C-1"), 119.98 (C-5), 127.15, 127.81, 127.89, 127.93, 127.96, 128.04, 128.16, 128.56, 128.49, 128.51, 128.62, 128.65, 128.69, 128.74, 128.80 (ArCH), 135.23–136.37 (6 \times ipso-C of benzylphospho ring with C–P coupling) 137.52, 137.77, 138.18 (3 × ipso-C of Bn ring), 139.64 (C-8), 150.25 (C-4), 153.11 (C-2), 155.33 (C-6); δ_P(161.8 MHz; $CDCl_3$; ¹H decoupled) -0.13, -0.86, -0.01 (3 s); m/z (FAB) 1480.4 [(M + H)⁺, 90%]; mass calcd for $C_{79}H_{81}N_5O_{18}P_3$ (M + H)+, 1480.47895; found 1480.47537.

 $3'-O-\alpha$ -D-Glucopyranosyl adenosine 2', 3'', 4''-trisphosphate (adenophostin A) (2). A mixture of 8 (256 mg, 0.17 mmol) and moist 20% Pd(OH)₂ on carbon (ca. 300 mg) in methanol (10.5 cm³), cyclohexene (5.5 cm³) and milliQ water (0.75 cm³) was heated at 80 °C for 4 h. The mixture was passed through a membrane filter to remove the catalyst washing well with MeOH and water. The filtrate was concentrated under reduced pressure with the resulting residue being purified on an MP1 AG ion-exchange column eluting with 0-100% 150 mM TFA. The relevant fractions (elution between 55-85%) were concentrated to give adenophostin A 2 (105 mg, 90%) as the free acid. $\delta_{\rm H}(270 \text{ MHz; } D_2 O) 3.59-3.77$ (6 H, m, H-2", H-5", H-5'_A, H-5'_B, H-6"_A, H-6"_B), 3.99 (1 H, q, $J_{3",4"} = J_{4",5"}$ 9.5, H-4"), 4.28 $(1 \text{ H}, \text{m}, J_{3',4'} 3.3, \text{H-4'}), 4.39 (1 \text{ H}, \text{q}, J_{2'',3''} = J_{3'',4''} 9.5, \text{H-3''}) 4.50$ (1 H, m, H-3'), 5.13 (1 H, d, J = 3.7 Hz, H-1"), 5.16 (1 H, m, H-2'), 6.20 (1 H, d, J_{1',2'} 6.2, H-1'), 8.25, 8.35 (2 H, 2 s, H-8, H-2); $\delta_{\rm C}(150.8$ MHz; D₂O) 60.25 (C-6"), 61.10 (C-5'), 70.50 (C-2"), 71.61 (C-5"), 73.13 (C-4"), 73.99 (C-3'), 75.94 (C-2' with C-P coupling), 78.14 (C-3" with C-P coupling), 84.56 (C-4'), 87.24 (C-1'), 98.30 (C-1"), 119.08 (C-5), 143.50 (C-8), 144.62 (C-2), 148.39 (C-4), 150.03 (C-6); δ_P (161.8 MHz; D₂O; ¹H decoupled) 0.25, 0.81, 1.17 (3 s); m/z (FAB) 668.1 [(M-H)-, 100%]; mass calcd for $C_{16}H_{27}N_5O_{18}P_3$ (M + H)⁺, 670.05585; found 670.05635.

N-2,3-Etheno-3'-O-a-D-glucopyranosyl adenosine 2', 3",4"-tris**phosphate (4).** To a solution of $2(11 \text{ mg}, 16.4 \mu \text{mol})$ in 50% aq. chloroacetaldehyde (1 cm³) was added NaOAc until pH 4-4.5 was attained. The solution was stirred at 37 °C for 48 h and was washed with ethyl acetate $(3 \times 25 \text{ cm}^3)$ and the aqueous layer was concentrated under reduced pressure. Purification using an MP1 AG ion-exchange column eluting with 0-100% 150 mM TFA (elution between 40-70%) gave the desired compound 4 (4.7 mg, 43%). Fluorescence (pH 7) (excitation) 296 nm, (emission) 412 nm; UV (H₂O)/nm λ_{max} 220 and 272; δ_{H} (270 MHz; D₂O) 3.68–3.94 (6 H, m, H-2", H-5", H-5'_A, H-5'_B, H-6"_A, H-6"_B), 4.11 $(1 \text{ H}, \mathbf{q}, J_{3'',4''} = J_{4'',5''} 9.1, \text{H-4''}), 4.43 (1 \text{ H}, \text{m}, \text{H-4'}), 4.50 (1 \text{ H}, \text{m})$ q, $J_{2'',3''} = J_{3'',4''}$ 9.1, H-3") 4.67 (1 H, m, $J_{3',4'}$ 3.3, H-3'), 5.24 (1 H, d, J_{1",2"} 3.2, H-1"), 5.39 (1 H, m, H-2'), 6.48 (1 H, d, J_{1',2'} 5.7, H-1'), 8.22, 8.87 (2 H, 2 d, J_{10,11} 2.2, H-10, H-11), 8.68, 9.35 (2 H, 2 s, H-8, H-2); δ_c(100.5 MHz; D₂O) 60.27 (C-6"), 61.07 (C-5'), 70.60 (C-2"), 71.70 (C-5"), 72.92 (C-4"), 73.83 (C-3'), 75.59 (C-2' with C-P coupling), 77.88 (C-3" with C-P coupling), 84.40 (C-4'), 87.67 (C-1'), 98.15 (C-1"), 114.38 (C-10). 119.08 (C-5),

121.88 (C-11), 137.76 (C-8, C-2), 143.05 (C-4), 144.59 (C-6); $\delta_{\rm P}(109.2 \text{ MHz}; D_2 \text{O}; {}^{1}\text{H} \text{ decoupled}) -0.17, 0.39, 0.77 (3 s);$ *m/z*(FAB) 694.0 [(M + H)⁺, 75%]; mass calcd for C₁₈H₂₇N₅O₁₈P₃ (M + H)⁺, 694.05640; found 694.05368.

8-Bromo-3'-O-a-D-glucopyranosyl adenosine 2', 3",4"-trisphosphate (5). To a stirred solution of adenophostin A 2 (22 mg, 32.9 µmol) in 0.5 M sodium acetate buffer (1 cm³, pH 4.3) was added a solution of Br₂ (23 mg, 0.14 mmol) in 0.5 M sodium acetate buffer (2 cm³, pH 4.3) dropwise. The reaction mixture was stirred in the dark at room temperature for 60 h monitoring the pH occasionally and adding additional buffer if necessary. The solution was partitioned between CHCl₃ (5 cm³) and water with the aqueous layer being treated with solid NaHSO₃ to remove excess Br₂. The aqueous layer was further extracted with CHCl₃ (3×5 cm³) and concentrated under reduced pressure. Purification using an MP1 AG ion-exchange column eluting with 0-100% 150 mM TFA (elution between 40-70%) gave the desired compound 5 (9.6 mg, 41%). $\delta_{\rm H}$ (400 MHz; D₂O) 3.58– 3.78 (6 H, m, H-2", H-5", H-5'_A, H-5'_B, H-6"_A, H-6"_B), 3.83 (1 H, $q, J_{3'',4''} = J_{4'',5''}$ 9.4, H-4''), 4.32 (2 H, m, H-4', H-3''), 4.53 (1 H, m, J_{3',4'} 5.3, H-3'), 5.26 (1 H, d, J_{1'',2''} 3.5, H-1"), 5.30 (1 H, m, H-2'), 6.16 (1 H, d, $J_{1',2'}$ 7.4, H-1'), 8.01 (1 H, s, H-2); $\delta_{\rm C}$ (150.8 MHz; D2O) 60.41 (C-6"), 62.00 (C-5'), 71.32 (C-2"), 72.16 (C-4") 72.30 (C-5"), 73.67 (C-3'), 74.37 (C-2' with C-P coupling), 77.187 (C-3" with C-P coupling), 85.56 (C-4'), 89.46 (C-1'), 98.12 (C-1"), 119.89 (C-5), 128.86 (C-8), 149.75 (C-4), 152.39 (C-2), 154.68 (C-6); $\delta_{\rm P}(161.8 \text{ MHz}; D_2O; {}^{1}\text{H} \text{ decoupled}) 3.67 \text{ and } 2.54 (2 \times$ brs integrating as 1:2 respectively); m/z (FAB) 746.0, 748.0 [(M–H)⁻, 45%]; mass calcd for $C_{16}H_{24}^{79}BrN_5O_{18}P_3$ (M–H)⁻, 745.95126 and C₁₆H₂₄⁸¹BrN₅O₁₈P₃ (M-H)⁻, 747.94922; found 745.94998 and 747.94975.

Acknowledgements

We thank the Wellcome Trust for Programme Grant Support (060554 to B.V.L.P. and 039662 to C.W.T.). We also thank Mr James J. Robinson for useful discussions on molecular modelling and Dr Andrew M. Riley, University of Bath, UK, for his invaluable advice on all aspects of this work.

References

- 1 M. J. Berridge, Nature, 1993, 361, 315-325.
- 2 M. J. Berridge, M. D. Bootman and P. Lipp, *Nature*, 1998, **395**, 645–648.
- 3 B. V. L. Potter and D. Lampe, Angew. Chem., Int. Ed. Engl., 1995, 34, 1933–1972.
- 4 A. M. Riley, A. J. Laude, C. W. Taylor and B. V. L. Potter, *Bioconjugate Chem.*, 2004, 15, 278–289.
- 5 M. Takahashi, T. Kagasaki, T. Hosoya and S. Takahashi, J. Antibiot., 1993, 46, 1643–1647.
- 6 M. Takahashi, K. Tanzawa and S. Takahashi, J. Biol. Chem., 1994, 269, 369–372.
- 7 S. Takahashi, T. Kinoshita and M. Takahashi, J. Antibiot., 1994, 47, 95–100.
- 8 V. Correa, A. M. Riley, S. Shuto, G. Horne, E. P. Nerou, R. D. Marwood, B. V. L. Potter and C. W. Taylor, *Mol. Pharmacol.*, 2001, 59, 1206–1215.
- 9 S. Shuto, K. Tatani, Y. Ueno and A. Matsuda, J. Org. Chem., 1998, 63, 8815–8824.
- 10 R. D. Marwood, S. Shuto, D. J. Jenkins and B. V. L. Potter, *Chem. Commun.*, 2000, 219–220.
- 11 J. Hirota, T. Michikawa, A. Miyawaki, M. Takahashi, K. Tanzawa, I. Okura, T. Furuichi and K. Mikoshiba, *FEBS Lett.*, 1995, 368, 248–252.
- 12 L. Missiaen, J. B. Parys, I. Sienaert, K. Maes, K. Kunzelmann, M. Takahashi, K. Tanzawa and H. De Smedt, J. Biol. Chem., 1998, 273, 8983–8986.
- 13 S. A. Morris, E. P. Nerou, A. M. Riley, B. V. L. Potter and C. W. Taylor, *Biochem. J.*, 2002, 367, 113–120.
- 14 R. D. Marwood, A. M. Riley, V. Correa, C. W. Taylor and B. V. L. Potter, *Bioorg. Med. Chem. Lett.*, 1999, 9, 453–458.
- 15 R. D. Marwood, D. J. Jenkins, V. Correa, C. W. Taylor and B. V. L. Potter, J. Med. Chem., 2000, 43, 4278–4287.

- 16 R. D. Marwood, A. M. Riley, D. J. Jenkins and B. V. L. Potter, J. Chem. Soc., Perkin Trans. 1, 2000, 1935–1947.
- 17 R. D. Marwood, V. Correa, C. W. Taylor and B. V. L. Potter, Tetrahedron: Asymmetry, 2000, 11, 397-403.
- 18 H. J. Rosenberg, A. M. Riley, V. Correa, C. W. Taylor and B. V. L. Potter, *Carbohydr. Res.*, 2000, **329**, 7–16.
- 19 H. J. Rosenberg, A. M. Riley, R. D. Marwood, V. Correa, C. W. Taylor and B. V. L. Potter, *Carbohydr. Res.*, 2001, **332**, 53–66.
- 20 H. J. Rosenberg, A. M. Riley, A. J. Laude, C. W. Taylor and B. V. L. Potter, J. Med. Chem., 2003, 46, 4860–4871.
- A. M. Riley and B. V. L. Potter, *Tetrahedron Lett.*, 1999, 40, 2213–2216.
 A. M. Riley, V. Correa, M. F. Mahon, C. W. Taylor and B. V. L.
- Potter, J. Med. Chem., 2001, 44, 2108–2117. 23 H. Abe, S. Shuto and A. Matsuda, J. Org. Chem., 2000, 65, 4315–
- 4325.
 24 S. Shuto, G. Horne, R. D. Marwood and B. V. L. Potter, *Chem.*
- *Eur. J.*, 2001, 7, 4937–4946.
- 25 M. de Kort, A. D. Regenbogen, H. S. Overkleeft, R. A. John Challiss, Y. Iwata, S. Miyamoto, G. A. van der Marel and J. H. van Boom, *Tetrahedron*, 2000, 56, 5915–5928.
- 26 M. de Kort, V. Correa, A. R. Valentijn, G. A. van der Marel, B. V. L. Potter, C. W. Taylor and J. H. van Boom, *J. Med. Chem.*, 2000, 43, 3295–3303.
- 27 M. De Kort, A. R. Valentijn, G. A. Van der Marel and J. H. Van Boom, *Tetrahedron Lett.*, 1997, **38**, 7629–7632.
- 28 M. De Kort, J. Luijendijk, G. A. Van der Marel and J. H. Van Boom, *Eur. J. Org. Chem.*, 2000, 3085–3092.
- 29 N. C. R. Van Straten, G. A. Van Der Marel and J. H. Van Boom, *Tetrahedron Lett.*, 1996, 37, 3599–3602.
- 30 N. C. R. Van Straten, N. M. A. J. Kriek, Z. A. C. Cziria, G. A. Van Der Marel and J. H. Van Boom, *Tetrahedron*, 1997, 53, 6539–6554.
- 31 N. C. R. Van Straten, G. A. Van Der Marel and J. H. Van Boom, *Tetrahedron*, 1997, **53**, 6523–6538.
- 32 N. C. R. Van Straten, G. A. Van Der Marel and J. H. Van Boom, *Tetrahedron*, 1997, **53**, 6509–6522.
- 33 H. Hotoda, K. Murayama, S. Miyamoto, Y. Iwata, M. Takahashi, Y. Kawase, K. Tanzawa and M. Kaneko, *Biochemistry*, 1999, 38, 9234–9241.
- 34 C. T. Murphy, A. M. Riley, C. J. Lindley, D. J. Jenkins, J. Westwick and B. V. L. Potter, *Mol. Pharmacol.*, 1997, **52**, 741–748.
- I. Bosanac, J. R. Alattia, T. K. Mal, J. Chan, S. Talarico, F. K. Tong, K. I. Tong, F. Yoshikawa, T. Furuichi, M. Iwai, T. Michikawa, K. Mikoshiba and M. Ikura, *Nature*, 2002, 420, 696–700.
 J. A. Secrist III, J. R. Barrio, N. J. Leonard and G. Weber,
- 36 J. A. Secrist III, J. R. Barrio, N. J. Leonard and G. Weber, *Biochemistry*, 1972, **11**, 3499–3506.
- 37 J. R. Barrio, J. A. Secrist III and N. J. Leonard, Proc. Natl. Acad. Sci. U. S. A., 1972, 69, 2039–2042.
- 38 E. W. van Tilburg, J. V. Kunzel, M. de Groote and A. P. Ijzerman, J. Med. Chem., 2002, 45, 420–429.
- 39 Y. Hayakawa and M. Kataoka, J. Am. Chem. Soc., 1998, 120, 12395– 12401.
- 40 S. Hanessian, T. J. Liak and B. Vanasse, Synthesis-Stuttgart, 1981, 396–397.
- 41 H. Hotoda, M. Takahashi, K. Tanzawa, T. Takahashi and M. Kaneko, *Tetrahedron Lett.*, 1995, 36, 5037–5040.
- 42 J. R. Barrio, J. A. Secrist III and N. J. Leonard, Biochem. Biophys. Res. Commun., 1972, 46, 597–604.
- 43 J. A. Secrist III, J. R. Barrio and N. J. Leonard, *Science*, 1972, **175**, 646–647.

- 44 R. Khazanchi, P. L. Yu and F. Johnson, J. Org. Chem., 1993, 58, 2552–2556.
- 45 D. Flaherty, P. Balse, K. Li, B. M. Moore and M. B. Doughty, *Nucleosides Nucleotides*, 1995, 14, 65–76.
- 46 B. E. Haley, Biochemistry, 1975, 14, 3852-3857.
- 47 R. A. Long, R. K. Robins and L. B. Townsend, J. Org. Chem., 1967, 32, 2751–2756.
- 48 K. Muneyama, R. J. Bauer, D. A. Shuman, R. K. Robins and L. N. Simon, *Biochemistry*, 1971, **10**, 2390–2395.
- 49 M. Ikehara and S. Uesugi, Chem. Pharm. Bull., 1969, 17, 348-354.
- 50 W. A. Wlassoff, M. I. Dobrikov, I. V. Safronov, R. Y. Dudko, V. S. Bogachev, V. V. Kandaurova, G. V. Shishkin, G. M. Dymshits and O. I. Lavrik, *Bioconjugate Chem.*, 1995, 6, 352–360.
- 51 A. E. V. Haschemeyer and A. Rich, J. Med. Biol., 1967, 27, 369-384.
- 52 D. B. Davies and S. S. Danyluk, *Biochemistry*, 13, pp. 4417–4434.
- 53 S. S. Tavale and H. M. Sobell, *J. Mol. Biol.*, 1970, **48**, 109–123.
- 54 L. Mao, Y. Wang, Y. Liu and X. Hu, J. Am. Chem. Soc., 2003, 125, 14216–14217.
- 55 L. Mao, Y. Wang, Y. Liu and X. Hu, J. Mol. Biol., 2004, 336, 787– 807.
- 56 J. Rahuel, C. Garcia-Echeverria, P. Furet, A. Strauss, G. Caravatti, H. Fretz, J. Schoepfer and B. Gay, J. Mol. Biol., 1998, 279, 1013– 1022.
- 57 N. Zacharias and D. A. Dougherty, *Trends Pharmacol. Sci.*, 2002, 23, 281–287.
- 58 B. Ahvazi, R. Coulombe, M. Delarge, M. Vedadi, L. Zhang, E. Meighen and A. Vrielink, *Biochem. J.*, 2000, 349, 853–861.
- 59 K. Nakajima, A. Yamashita, H. Akama, T. Nakatsu, H. Kato, T. Hashimoto, J. Oda and Y. Yamada, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 4876–4881.
- 60 M. J. Adams, G. H. Ellis, S. Gover, C. E. Naylor and C. Phillips, *Structure*, 1994, 2, 651–668.
- 61 J. S. Marchant, M. D. Beecroft, A. M. Riley, D. J. Jenkins, R. D. Marwood, C. W. Taylor and B. V. L. Potter, *Biochemistry*, 1997, 36, 12780–12790.
- 62 J. C. Ma and D. A. Dougherty, Chem. Rev., 1997, 97, 1303-1324.
- 63 S. Mecozzi, A. P. West Jr. and D. A. Dougherty, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 10566–10571.
- 64 M. A. Abdallah, J. F. Biellmann, B. Nordstroem and C. I. Braenden, *Eur. J. Biochem.*, 1975, **50**, 475–481.
- 65 K. W. Olsen, R. M. Garavito, M. N. Sabesan and M. G. Rossmann, J. Mol. Biol., 1976, 107, 571–576.
- 66 H. M. Ke, Y. P. Zhang and W. N. Lipscomb, Proc. Natl. Acad. Sci. U. S. A., 1990, 87, 5243–5247.
- 67 D. D. Leonidas, R. Shapiro, L. I. Irons, N. Russo and K. R. Acharya, *Biochemistry*, 1999, 38, 10287–10297.
- 68 D. D. Leonidas, R. Shapiro, L. I. Irons, N. Russo and K. R. Acharya, *Biochemistry*, 1997, 36, 5578–5588.
- 69 D. A. Sawyer and B. V. L. Potter, J. Chem. Soc., Perkin Trans. 1, 1992, 923–932.
- 70 G. A. Mignery, C. L. Newton, B. T. Archer and T. C. Sudhof, J. Biol. Chem., 265, pp. 12679–12685.
- 71 J. Miyazaki, S. Takaki, K. Araki, F. Tashiro, A. Tominaga, K. Takatsu and K. Yamamura, *Gene*, 79, pp. 269–277.
- 72 H. Sugawara, M. Kurosaki, M. Takata and T. Kurosaki, *EMBO J.*, 16, pp. 3078–3088.
- 73 H. Sugawara, M. Kurosaki, M. Takata and T. Kurosaki, *EMBO J.*, 16, pp. 3078–3088.
- 74 T. J. Cardy, D. Traynor and C. W. Taylor, *Biochem. J.*, 328 (Pt 3), pp. 785–793.